In the clinical setting, the chimeric mAb girentuximab is mostly tested for targeting of CAIX in clear cell renal cell carcinoma (ccRCC) (219), but no clinical studies have been performed on primary lung cancer. This evidence concerns the gene CA9 and lung carcinoma.